• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Exelixis, Inc. - Common Stock (NQ:EXEL)

    52.20 -4.50 (-7.94%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,410,853
    Open 52.92
    Bid (Size) 51.63 (100)
    Ask (Size) 53.22 (100)
    Prev. Close 56.70
    Today's Range 51.76 - 55.44
    52wk Range 33.76 - 57.57
    Shares Outstanding 315,048,788
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating ↗
    Via Chartmill
    News headline image
    Exelixis Q2 Earnings Call Highlights ↗
    Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +19.8%
    +19.8%
    1 Month
    -6.0%
    -6.0%
    3 Month
    +7.2%
    +7.2%
    6 Month
    +22.4%
    +22.4%
    1 Year
    +39.3%
    +39.3%

    More News

    Read More
    Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered ↗
    Via Chartmill
    News headline image
    Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
    Via The Motley Fool
    Topics Economy
    Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector ↗
    Via Chartmill
    Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗
    Via Chartmill
    EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Case for Value Investors ↗
    Via Chartmill
    News headline image
    Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    3 Under-the-Radar Stocks to Buy and Hold ↗
    Via The Motley Fool
    News headline image
    Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum ↗
    Via Chartmill
    Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC ↗
    Via Chartmill
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
    Via MarketBeat
    News headline image
    Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Prediction: This Stock Could Double By 2031 ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Exelixis (EXEL) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
    From Exelixis, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Exelixis, Inc. - Common Stock publicly traded?
    Yes, Exelixis, Inc. - Common Stock is publicly traded.
    What exchange does Exelixis, Inc. - Common Stock trade on?
    Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Exelixis, Inc. - Common Stock?
    The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
    What is the current price of Exelixis, Inc. - Common Stock?
    The current price of Exelixis, Inc. - Common Stock is 52.20
    When was Exelixis, Inc. - Common Stock last traded?
    The last trade of Exelixis, Inc. - Common Stock was at 08/06/26 04:00 PM ET
    What is the market capitalization of Exelixis, Inc. - Common Stock?
    The market capitalization of Exelixis, Inc. - Common Stock is 16.45B
    How many shares of Exelixis, Inc. - Common Stock are outstanding?
    Exelixis, Inc. - Common Stock has 16B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.